154 related articles for article (PubMed ID: 38332225)
41. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
42. Microlocalization and clinical significance of stabilin-1
Wang B; Huang H; Yang M; Yang W; Liu Z; Hou W; Zeng H; He Z; Lin T; Huang J
World J Urol; 2020 Mar; 38(3):709-716. PubMed ID: 31302753
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.
Hodgson A; Jungbluth AA; Katabi N; Xu B; Downes MR
Virchows Arch; 2020 Apr; 476(4):535-542. PubMed ID: 31485721
[TBL] [Abstract][Full Text] [Related]
45. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma.
van der Horst G; Bos L; van der Pluijm G
Mol Cancer Res; 2012 Aug; 10(8):995-1009. PubMed ID: 22714124
[TBL] [Abstract][Full Text] [Related]
46. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
47. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
48. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
[TBL] [Abstract][Full Text] [Related]
49. Mass cytometry reveals immune atlas of urothelial carcinoma.
Zhang Q; Zhang W; Lin T; Lu W; He X; Ding Y; Chen W; Diao W; Ding M; Shen P; Guo H
BMC Cancer; 2022 Jun; 22(1):677. PubMed ID: 35725444
[TBL] [Abstract][Full Text] [Related]
50. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
51. [Non-urothelial tumors of the urinary tract].
Mikuz G
Verh Dtsch Ges Pathol; 1993; 77():180-98. PubMed ID: 7511278
[TBL] [Abstract][Full Text] [Related]
52. Amyloidosis of the bladder and association with urothelial carcinoma: report of 29 cases.
Sirohi D; Gandhi J; Amin MB; Luthringer DJ
Hum Pathol; 2019 Nov; 93():48-53. PubMed ID: 31425694
[TBL] [Abstract][Full Text] [Related]
53. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.
Garg M
Cancer Metastasis Rev; 2015 Dec; 34(4):691-701. PubMed ID: 26328525
[TBL] [Abstract][Full Text] [Related]
54. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
[TBL] [Abstract][Full Text] [Related]
55. Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma.
Donelan W; Crispen PL; Kusmartsev S
Methods Mol Biol; 2023; 2684():167-175. PubMed ID: 37410234
[TBL] [Abstract][Full Text] [Related]
56. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
[TBL] [Abstract][Full Text] [Related]
57. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
58. Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
Jones TD; Cheng L
Urol Oncol; 2021 May; 39(5):286-290. PubMed ID: 35550107
[TBL] [Abstract][Full Text] [Related]
59. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
60. Urinary tract cytology showing variant morphology and divergent differentiation.
Arshia A; Hassan FA; Hensley PJ; Allison DB
Cytopathology; 2024 Mar; 35(2):199-212. PubMed ID: 37919868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
